China A roundup of some of the most significant recent stories from the Chinese pharmaceutical industry, including a slate of international investment which seems to suggest that – despite ongoing political tensions – China remains an attractive market for multinational pharma. AstraZeneca defies geopolitics to bet on China – Financial…
India Top stories from Indian pharma including Dr Reddy’s move to US online platforms, Aspen/Serum Institute’s vaccine deal for Africa, Aurobindo’s USD 37.7 million investment in subsidiary CuraTeQ and Biocon’s FDA troubles. Indian pharma market growth in August 12.1 percent (The Economic Times India) According to a study from the…
UK Thomas Broeer, managing director UK and Ireland for Aurobindo, has been at the helm of Aurobindo’s UK subsidiary, Milpharm Limited for almost two years and here discusses the UK market’s strengths, the potential impact of Brexit on the pharmaceutical industry and the pricing structures in place in the UK. …
Colombia Aurobindo’s regional head, Kamlesh Thakkar, discusses how the company is truly benefiting the healthcare landscape in Colombia, while describing his experience in changing the mindset concerning the use of generics in the top hospitals of the country and shares the origins of Aurobindo’s healthier life campaign. To begin, Mr. Thakkar,…
Pharma Leo de Haan of Aurobindo discusses how to maintain a profitable business in times of rock-bottom generics prices in the Netherlands, the resulting second pillar of specialty products for the company and the growth ambitions for the affiliate over the next few years. You have extensive experience in the generics…
Indian When Indian generics company Aurobindo established itself in Portugal in 2010, the affiliate was faced with some difficult choices. As the latest company to enter the Portuguese generic market, Aurobindo had the lowest prices in the market, which was not attractive to the pharmacy channel. Pedro Merlini, country manager of…
See our Cookie Privacy Policy Here